Pluri Inc. PLUR 深 滬
等待開盤 03-27 09:30:00 美东时间
3.22
-0.110
-3.30%
華盛通- 最 高3.3299
- 今 開3.27
- 成交量 1.13万股
- 最 低 3.21
- 昨 收 3.33
- 總市值 3236.33万
- 52周最高 7.13
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 2.82
- 委 比 69.47%
- 總股本 1005.07万
- 歷史最高 400.00
- 量 比 1.18
- 振 幅 3.60%
- 歷史最低 2.82
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pluri Signs Agreement With Beneficiary Owned By Chairman Alejandro Weinstein For Additional $2.5M Investment In Co.
Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by
03-26 20:39
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
Pluri Inc., a biotechnology company, announced that Alejandro Weinstein, its Chairman and major shareholder, has made an additional $2.5 million investment at a 30% premium to the market price. This follows a previous $2.5 million investment and demonstrates Weinstein's confidence in the company's assets, technology, and long-term value. The investment includes 625,000 common shares and warrants exercisable at $4.25 per share. Proceeds will be us...
03-26 12:30
Pluri Regains Nasdaq Compliance, Restoring Listing Stability
An update from Pluri ( ($PLUR) ) is now available. On January 20, 2026, Pluri I...
03-02 22:28
Pluri Regains Nasdaq Listing Compliance Under Rule 5550(b)(2)
Pluri Regains Nasdaq Listing Compliance Under Rule 5550(b)(2) Pluri Inc. said it has regained compliance with Nasdaq Listing Rule 5550(b)(2) after previously receiving a deficiency notice for failing to maintain a minimum $35 million market value of listed securities required for continued listing o
03-02 22:01
Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech
The China National Intellectual Property Administration (CNIPA) has granted Pluri Biotech Ltd., a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation
02-18 21:03
Pluri Inc. Granted China Patent for Large-Scale 3D Immune Cell Expansion Technology
Pluri Inc. Granted China Patent for Large-Scale 3D Immune Cell Expansion Technology Pluri Inc. said China’s National Intellectual Property Administration has granted its subsidiary a patent for a proprietary 3D immune cell expansion and activation system for large-scale manufacturing. The company sa
02-18 21:02
Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate
Pluri (NASDAQ:PLUR) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.65) by 9.23 percent. This is a 33.96 percent decrease over losses of $(0.53) per share from the same
02-13 06:21
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
Pluri, Inc. and Resbiomed Technologies OOD have completed the first phase of their collaboration focused on developing placenta-derived biomaterials for regenerative medicine. The program, executed via Pluri’s CDMO division, PluriCDMO™, aimed to enhance and standardize the production of collagen-rich materials. The next phase will focus on advancing process reproducibility and manufacturing readiness. The partnership leverages Pluri’s placenta-ba...
01-22 14:15
Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production
Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today
2025-12-22 20:08
